A Study to Evaluate the Effect of Renal Function on the Biological Activity of Telavancin

Inclusion Criteria:

- Weighs at least 45 kg and body mass index of 18 to 40 kg/m2, inclusive

- An estimated creatinine clearance value based on Cockcroft-Gault method of:

- >80 mL/min for subjects with normal renal function

- <30 mL/min for subjects with severe renal impairment

- receiving hemodialysis three times a week for subjects with end stage renal
impairment

- If female, the subject is at least 2 years postmenopausal, surgically sterile or
practicing effective birth control, and is not pregnant or lactating

- Good venous access

Exclusion Criteria:

- History of any clinically significant acute illness (other than renal disease and
conditions related to the renal disease in renal impairment subjects, such as stable
diabetes or hypertension)

- Has had a kidney transplant that is still functioning

- History of unexplained syncope, cardiac arrest, unexplained cardiac arrythmia or
torsade de pointes, structural heart disease, prolonged QT interval, or family history
of long QT syndrome

- Known hypersensitivity to telavancin or any of the excipients in the formulation, or a
history of severe allergic or anaphylactic reactions

- History of consuming more than 7 units of alcoholic beverages per week, or history of
alcoholism or substance abuse within past 2 years

- Known to be positive for human immunodeficiency virus antibody

- For subjects with normal renal function, has had treatment with prescription or
non-prescription drugs, including complementary and alternative medicines or over-the
counter medications, with the exception of oral contraceptives, hormone replacement
therapy, daily aspirin, and occasional use of acetaminophen within the past 14 days

- For subjects with renal impairment, has not been on a stable dose of concomitant
medications for at least 2 weeks prior to study start or is taking any medication that
would interfere with the evaluation of televancin in this study

- Has received an experimental agent within 30 days or ten half-lives, whichever is
longer, prior to study drug administration

- Has had any significant blood loss, donated one unit (450 mL) of blood or more, or
received a transfusion of any blood or blood products within 60 days or donated plasma
within 7 days prior to admission